EP2491919B2 - Pharmaceutical solution of taxanes comprising ph regulator and preparation method thereof - Google Patents

Pharmaceutical solution of taxanes comprising ph regulator and preparation method thereof Download PDF

Info

Publication number
EP2491919B2
EP2491919B2 EP10824478.1A EP10824478A EP2491919B2 EP 2491919 B2 EP2491919 B2 EP 2491919B2 EP 10824478 A EP10824478 A EP 10824478A EP 2491919 B2 EP2491919 B2 EP 2491919B2
Authority
EP
European Patent Office
Prior art keywords
emulsion
solution
added
taxanes
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Not-in-force
Application number
EP10824478.1A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2491919A4 (en
EP2491919B1 (en
EP2491919A1 (en
Inventor
Jianming Chen
Baoan Gao
Li Deng
Qiuxia Yang
Jing Sun
Wei Liu
Peng GU
Yingying Zhang
Jialiang Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Tasly Diyi Pharmaceutical Co Ltd
Original Assignee
Jiangsu Tasly Diyi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43899845&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2491919(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jiangsu Tasly Diyi Pharmaceutical Co Ltd filed Critical Jiangsu Tasly Diyi Pharmaceutical Co Ltd
Priority to PL10824478T priority Critical patent/PL2491919T5/pl
Publication of EP2491919A1 publication Critical patent/EP2491919A1/en
Publication of EP2491919A4 publication Critical patent/EP2491919A4/en
Application granted granted Critical
Publication of EP2491919B1 publication Critical patent/EP2491919B1/en
Publication of EP2491919B2 publication Critical patent/EP2491919B2/en
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to the field of pharmaceutical preparations technology. More specially, the present invention relates to a pharmaceutical solution of taxanes comprising a pH regulator and preparation method thereof.
  • Taxanes include paclitaxel (trade name: Taxol) and docetaxel (trade name: Taxotem), two types of anti-cancer drugs of taxanes approved by Food & Drug Administration (FDA). They both belong to water-insoluble drugs, which can hardly be dissolved in water (about 4ug/ml of water-solubility) and only 2%-4% is absorbed after oral administration. Hence, they can only be administrated intravenously.
  • available paclitaxel injection is a colorless viscous concentrated solution prepared by a mixed solvent of polyoxyethylene castor oil and anhydrous ethanol in the ratio of 50:50 (v/v).
  • dimethylacetamide could cause multiple severe injuries on mice and rats, such as weight loss, atrophy of the retina, change of brain electric wave, as well as a lot of injuries to organs of lung, stomach, liver and kidney etc.
  • the key technology on which is focused mainly is the properties of selected material such as biocompatibility, in vivo tolerance and stability of dosage form.
  • the clinical application is still restricted on account of low drug loading and short stabilization time, therefore making it impossible to reach an effectively therapeutic concentration.
  • no toxic solubilizer was contained, for example polyoxyethylene castor oil, Tween-80, dimethylacetamide, oleic acid and PVP etc, which finally makes its safety and stability improved significantly.
  • the present invention is a further research based on the Chinese patent application (Pat. Appl. No.: 200810100234.8 ). It was found that dispersion of emulsion in pharmaceutical solution, within a specific range of pH value, would make stabilization time and appearance better than that could be expected. The stabilization time was prolonged markedly; there was no floating oil on the surface of dispersed solution and the appearance was desirable. Clinically, safety and effectiveness of drugs were further improved. Consequently, the present invention belongs to an improved intravenous infusion preparation of taxanes and preparation method thereof.
  • the present invention provides a pharmaceutical composition of taxanes, prepared from two parts of pharmaceutical preparations: a pharmaceutical solution of taxanes and an emulsion.
  • the pharmaceutical solution contains a pH regulator, which is used to adjust pH value to 2.0 ⁇ 4.0.
  • the present invention is achieved by mixing the pharmaceutical solution and the emulsion in a ratio of 1:10 ⁇ 100 (v/v), preferably 1:20 ⁇ 50 (v/v), most preferably 1:25(v/v).
  • pH regulator due to the addition of pH regulator into the pharmaceutical solution of taxanes before used, which is used to adjust pH to 2.0 ⁇ 4.0, strong stability will be exhibited after mixing with an emulsion for injection.
  • the present invention provides a pharmaceutical solution of taxanes containing taxanes, a pH regulator and a solvent.
  • the proportions of ingredients are as follows: Taxanes 1 ⁇ 8%(g/ml) pH regulator proper amount sufficient to adjust pH to 2.0 ⁇ 4.0
  • the balance is a solvent.
  • the solvent is one or more solvents selected from the group consisting of PEG-200, PEG-300, PEG-400, and PEG-600.
  • the proportions of ingredients are as follows: Taxanes 1 ⁇ 6%(g/ml) pH regulator proper amount sufficient to adjust pH to 2.0 ⁇ 3.98
  • the balance is a solvent.
  • the solvent is one or more solvents selected from the group consisting of PEG-200, PEG-300, PEG-400, and PEG-600.
  • pH value is adjusted to 3.0 ⁇ 3.98 in the present invention.
  • the taxanes are any one of taxanes, preferably commercially available paclitaxel or docetaxel.
  • the pH regulator is a water-soluble acid, including one or more kinds selected from the group consisting of citric acid, lactic acid, malic acid, hydrochloric acid, acetic acid, phosphoric acid and tartaric acid, preferably citric acid.
  • a method of preparing solution of the present invention includes steps of dissolving taxanes and the pH regulator in a solvent.
  • the method includes steps of: weighing paclitaxel or docetaxel; adding paclitaxel or docetaxel into a solvent; dissolved by heating and stirring at 50 ⁇ 100°C or by shearing; diluting the mixture with the solvent; adjusting pH to 2.0 ⁇ 4.0 with the pH regulator; adding 0.01% ⁇ 3% (g/ml) activated carbon for injection to perform adsorption by heating at 25 ⁇ 100°C for 15-120 min; then filtering, separately packaging, cap-sealing and sterilizing to obtain the pharmaceutical solution of taxanes.
  • the present invention provides a kit comprising a pharmaceutical solution of taxanes and an emulsion loaded in two separate vessels that are arranged in a combined manner for clinical application. More particularly, the kit of the present invention comprises the pharmaceutical solution of taxanes and a medicinal emulsion in a ratio of 1:10 ⁇ 10:1, preferably 1:1, which are loaded in two separate plastic or glass bottles arranged in a combined manner in a same large vessel. Generally speaking, the present kit is designed desirably for a one-time use dosage.
  • the emulsion is an oil-water mixed emulsified preparation, a non-uniformly dispersed system formed by dispersion of oils or oil-solutions in dispersion medium in the form of liquid drops. It includes oral emulsion and intravenous infusion emulsion.
  • the emulsion of the present invention is intravenous infusion emulsion, preferably fat emulsion for intravenous infusion, for example 20% long/medium chain fat emulsion, 20% long chain fat emulsion etc.
  • the emulsion of the present invention is commercially available emulsion for injection or the emulsion specifically prepared in accordance with the prior arts, comprising, generally speaking, oil for injection, emulsifier, antioxidant, isotonic regulator, pH regulator and water for injection.
  • the oil for injection may be one or more oils selected from a group consisting of caprylic capric triglyceride, caprylic monoglyceride, caprylic diglyceride, caprylic triglyceride, Ganoderma lucidum spore oil, capric monoglyceride, capric diglyceride, capric triglyceride, caprylic capric monoglyceride, coix seed oil, Brucea Javanica oil, Herba Artemisiae Annuae oil, caprylic capric diglyceride, soybean oil, fish oil, linseed oil, helianthus annuus seed oil, evening primrose oil, sea buckthorn oil, zedoary turmeric oil, safflower seed oil, sesame oil, corn oil, elemene oil and garlic oil at a concentration of 1 ⁇ 30% (g/ml).
  • the concentration (g/ml) of oils in emulsion is indicated by grams of oil per milliliter of the
  • the oil for injection is one or more oils selected from the group consisting of caprylic capric triglyceride and soybean oil at a concentration of 10 ⁇ 30% (g/ml).
  • the emulsifier may be one or more emulsifiers selected from the group consisting of soybean phospholipid, yolk phospholipid, dimyristoyl phosphatidyl choline (DMPC), dipalmitoyl phosphatidylcholine (DPPC), distearoyl phosphatidylcholine (DSPC), dioleoyl-phosphatidylcholine(DOPC), palmitoyl-oleoyl phosphatidylcholine, distearoyl phosphatidylethanolamine (DSPE) and poloxamer 188 at a concentration of 0.5 ⁇ 5% (g/ml), preferably the emulsifier is one or more kinds selected from the group consisting of soybean phospholipid and yolk phospholipid at a concentration of 0.8 ⁇ 3% (g/ml).
  • the concentration (g/ml) of the emulsifier in emulsion is indicated by grams of emulsifier per milliliter of the emulsion.
  • the antioxidant is tocopherol at a concentration of 0 ⁇ 0.5% (g/ml), preferably 0 ⁇ 0.3% (g/ml).
  • the isotonic regulator may be one or more kinds selected from the group consisting of glycerol, sorbitol, mannitol, glucose and sodium chloride etc, preferably glycerol.
  • the pH regulator may be one or more kinds selected from the group consisting of citric acid, malic acid, hydrochloric acid, acetic acid, lactic acid, sodium carbonate, sodium bicarbonate and sodium hydroxide, preferably sodium hydroxide, with which pH value is adjusted to 6.0 ⁇ 9.0, preferably 6.5 ⁇ 8.5.
  • the intravenous infusion emulsion is prepared in accordance with routine methods in the prior art: oil for injection is mixed with antioxidant and heated to 50 ⁇ 90°C, then an emulsifier is added and dissolved by stirring or shearing to obtain oil phase; isotonic regulator and stabilizer are added to a proper amount of water for injection and heated to 50 ⁇ 90°C, making them dissolved by stirring to obtain water phase; the resulted oil phase and water phase are mixed at 50 ⁇ 90°C followed by emulsification by use of a shear emulsifying machine or stirring emulsification for 5-60 min at a rotation speed of 5000-30000 rpm to obtain a primary emulsion.
  • the obtained primary emulsion is further emulsified, diluted to volume with water for injection and its pH value is adjusted to 6.0 ⁇ 9.0. Then the resultant emulsion is filtrated, separately packaged, charged with nitrogen, cap-sealed and sterilized, thus the emulsion is obtained.
  • a method for preparing an emulsion includes steps of dissolving an emulsifier either in oil for injection or water.
  • the primary emulsion is further emulsified by high-pressure homogenizers under pressure of 5000-25000psi.
  • the sterilization method in the preparation of emulsions includes using rotary high-pressure steam sterilizer, circulating vapor or micro-porous filter membrane, wherein the high-temperature sterilization temperature is 100-121 °C and the time is 8 ⁇ 45 min.
  • the filtrating equipment includes but is not limited to micro-porous filter membrane, sand-filter rod, sintered filter funnel or capsule filter etc.
  • the final emulsion is a white or off-white emulsified liquid with opalescence, and the average particle size of the emulsion micro-particles ranges from 100 to 500nm, with a pH value from 6.0 ⁇ 9.0.
  • the present invention provides a method of using the pharmaceutical solution of taxanes, including dispersing the pharmaceutical solution of taxanes into a medicinal emulsion in a ratio of 1: 10 ⁇ 100 by volume, preferably 1: 25 by volume, and shaking well for intravenous drip.
  • the pharmaceutical solution dispersed by emulsion can be added into normal saline or glucose solution for injection, when used.
  • the paclitaxel intravenous injection prepared in accordance with the method of Example 1 was taken as an example to make research on a variety of changes in drug content, particle size and appearance.
  • Investigation method 4 ml pharmaceutical solution was dispersed into 100ml emulsion and shaken well.
  • the drug content and particle size of the dispersion solution were determined at different time-points by HPLC and a particle size analyzer, respectively; when determining the drug content at the different time-points, appropriate amount of dispersion solutions was extracted with injectors and filtrated firstly by 0.45 ⁇ m micro-porous filter membrane and then the drug contents in filtrates were determined to calculate labeled percentage amount, which was used to estimate whether drug crystal was precipitated or not; the particle size was measured directly; and the appearance was observed with naked eyes.
  • Table 1 The results are summarized in Table 1.
  • the docetaxel intravenous injection prepared in accordance with the method of Example 2 was taken as an example to make research on a variety of changes in drug content, particle size and appearance.
  • Investigation method 4 ml pharmaceutical solution was dispersed into 100ml emulsion and shaken well.
  • the drug content and particle size of the dispersion solution were determined at different time-points by HPLC and a particle size analyzer, respectively; when determining the drug content at the different time-points, appropriate amount of dispersion solutions was extracted with injectors and filtrated firstly by 0.45 ⁇ m micro-porous filter membrane and then the drug contents in filtrates were determined to calculate labeled percentage amount, which was used to estimate whether drug crystal was precipitated or not; the particle size was measured directly; and the appearance was observed with naked eyes.
  • Table 2 The results are summarized in Table 2.
  • Example 16 4 pharmaceutical solutions were prepared.
  • the pH value was respectively regulated to 2.04, 2.68, 3.20, and 3.98 with citric acid, and similarly the pharmaceutical solutions were dispersed in commercially available emulsions in light of method of Example 16 in a ratio of 1:25 by volume, shaken well to obtain the test sample.
  • Example 16 4 pharmaceutical solutions were prepared.
  • the pH value was regulated with sodium hydroxide or hydrochloric acid to 4.50, 5.61 , 6.87 and 7.53, and similarly the pharmaceutical solutions were dispersed in commercially available emulsions in light of method of Example 16 in a ratio of 1:25 by volume, shaken well, then the drug content was determined to obtain the control samples.
  • the drug content and particle size of the test sample and control sample were determined at different time-points by HPLC and a particle size analyzer, respectively.
  • appropriate amount of dispersion solutions was extracted with injectors and filtrated firstly by 0.45 ⁇ m micro-porous filter membrane and then the drug contents in filtrates were determined to calculate labeled percentage amount, which was used to estimate whether drug crystal was precipitated or not.
  • the particle size was measured directly and the appearance was observed with naked eyes.
  • Table 3 investigation on stability of dispersion solution between control and test sample (the emulsion for dispersion was commercially available) A.
  • Stabilization time of emulsion dispersion solution of the pharmaceutical solution of the present invention having specific pH value within the range of 2-4 was far longer than the control dispersion solution with pH value of 4 or more.
  • the appearance no floating oil had occurred in the dispersion solution of the present invention with a pH value within the range of 2 ⁇ 4, which having a better appearance and overcoming the drawback of floating oil unexpectedly, while more floating oil in the dispersion solution of control sample with a pH value of 4 or more, having a great deal of oil grease adhering on wall and the floating oil increased with time elapsed.
  • the particle size did not show any significant change before drug precipitated, and tended to become larger with drug precipitated.
  • oleic acid was added based on PEG-400 in an amount of 0.01 ⁇ 5%.
  • 0.3%, 1.0% and 5.0% oleic-acid/PEG-400 solutions were prepared respectively, which was used as a solvent to prepare 25mg/ml paclitaxel solution as a contrast solution.
  • a pharmaceutical solution was prepared in accordance with the Example 16 as a test solution. 4 ml test and contrast solutions were dispersed respectively into 100ml commercially available emulsions in Example 16, shaken well to obtain a measuring sample. The drug contents of the dispersion solution were determined at different time-points by HPLC.
  • Example 3 As suggested in Chinese patent application (Patent Appl. No.: 200410025522.3 ), it was mainly composed of paclitaxel, Tween-80, PVP, lecithin and solvent for injection.
  • the closest method to the present invention was Example 3, having a formulation of 1.8g paclitaxel, 22g phospholipid, 40g propylene glycol, balanced with anhydrous ethanol to 100ml.
  • a pharmaceutical solution was prepared as a contrast solution
  • paclitaxel solution was prepared according to method of Example 16 of the present invention as a test solution. 4 ml test and contrast solutions were dispersed respectively into 100ml commercially available emulsions in Example 16, shaken well to obtain measuring sample.
  • the drug content of the dispersion solution was determined at different time-points by HPLC.
  • appropriate amount of dispersion solution was extracted with injectors and filtrated firstly by 0.45 ⁇ m micro-porous filter membrane and then the paclitaxel contents in filtrates were determined to calculate labeled percentage amount, which was used to estimate whether drug crystal was precipitated or not.
  • labeled percentage amount which was used to estimate whether drug crystal was precipitated or not.
  • the appearance was observed with naked eyes. The results are summarized in Table 6.
  • Example 1 paclitaxel intravenous infusion preparation and a kit thereof
  • Afore-obtained paclitaxel solution and medicinal emulsion were respectively loaded in plastic or glass bottles, which were packaged up in a ratio of 1:1 in a same large vessel.
  • the paclitaxel solution can be added and evenly dispersed in the medicinal emulsion in a ratio of 1:25 by volume to perform intravenous drip directly; or the pharmaceutical solution can also be firstly added into the emulsion and then a normal saline injection with a predetermined amount of normal saline or glucose solution for injection is added to perform the injection.
  • Example 2 docetaxel intravenous infusion preparation and a kit thereof
  • Afore-obtained docetaxel solution and medicinal emulsion were respectively loaded in plastic or glass bottles, which were packaged up in a ratio of 1:1 in a same large vessel.
  • the pharmaceutical solution When used, the pharmaceutical solution can be added and evenly dispersed in the emulsion in a ratio of 1:25 by volume to perform intravenous drip directly.
  • Example 3 paclitaxel intravenous infusion preparation and a kit thereof
  • Afore-obtained paclitaxel solution and medicinal emulsion were respectively loaded in plastic or glass bottles, which were packaged up in a ratio of 1:1 in a same large vessel.
  • the pharmaceutical solution When used, the pharmaceutical solution can be added and evenly dispersed in the emulsion in a ratio of 1:50 by volume to perform intravenous drip directly.
  • Example 4 docetaxel intravenous infusion preparation and a kit thereof
  • Afore-obtained docetaxel solution and medicinal emulsion were respectively loaded in plastic or glass bottles, which were packaged up in a ratio of 1:1 in a same large vessel.
  • the pharmaceutical solution can be added and evenly dispersed in the emulsion in a ratio of 1:30 by volume to perform intravenous drip directly.
  • Example 5 paclitaxel intravenous infusion preparation and a kit thereof
  • Afore-obtained paclitaxel solution and medicinal emulsion were respectively loaded in plastic or glass bottles, which were packaged up in a ratio of 1:1 in a same large vessel.
  • the pharmaceutical solution When used, the pharmaceutical solution can be added and evenly dispersed in the emulsion in a ratio of 1:70 by volume to perform intravenous drip directly.
  • Example 6 docetaxel intravenous infusion preparation and a kit thereof (not falling under the present invention)
  • Afore-obtained docetaxel solution and medicinal emulsion were respectively loaded in plastic or glass bottles, which were packaged up in a ratio of 1:1 in a same large vessel.
  • the pharmaceutical solution When used, the pharmaceutical solution can be added and evenly dispersed in the emulsion in a ratio of 1:80 by volume to perform intravenous drip directly.
  • Example 7 paclitaxel intravenous infusion preparation and a kit thereof (not falling under the present invention)
  • Afore-obtained paclitaxel solution and medicinal emulsion were respectively loaded in plastic or glass bottles, which were packaged up in a ratio of 1:1 in a same large vessel.
  • the pharmaceutical solution When used, the pharmaceutical solution can be added and evenly dispersed in the emulsion in a ratio of 1:10 by volume to perform intravenous drip directly.
  • Example 8 docetaxel intravenous infusion preparation and a kit thereof (not falling under the present invention)
  • Afore-obtained docetaxel solution and medicinal emulsion were respectively loaded in plastic or glass bottles, which were packaged up in a ratio of 1:1 in a same large vessel.
  • the pharmaceutical solution When used, the pharmaceutical solution can be added and evenly dispersed in the emulsion in a ratio of 1:25 by volume to perform intravenous drip directly.
  • Example 9 paclitaxel intravenous infusion preparation and a kit thereof
  • Afore-obtained paclitaxel solution and medicinal emulsion were respectively loaded in plastic or glass bottles, which were packaged up in a ratio of 1:1 in a same large vessel.
  • the pharmaceutical solution When used, the pharmaceutical solution can be added and evenly dispersed in the emulsion in a ratio of 1:60 by volume to perform intravenous drip directly.
  • Example 10 docetaxel intravenous infusion preparation and a kit
  • the pharmaceutical solution can be added and evenly dispersed in the emulsion in a ratio of 1:100 by volume to perform intravenous drip directly.
  • Example 11 paclitaxel intravenous infusion preparation and a kit thereof
  • Afore-obtained paclitaxel solution and medicinal emulsion were respectively loaded in plastic or glass bottles, which were packaged up in a ratio of 1:1 in a same large vessel.
  • the pharmaceutical solution When used, the pharmaceutical solution can be added and evenly dispersed in the emulsion in a ratio of 1:25 by volume to perform intravenous drip directly.
  • Example 12 docetaxel intravenous infusion preparation and a kit thereof
  • Afore-obtained docetaxel solution and medicinal emulsion were respectively loaded in plastic or glass bottles, which were packaged up in a ratio of 1:1 in a same large vessel.
  • the pharmaceutical solution When used, the pharmaceutical solution can be added and evenly dispersed in the emulsion in a ratio of 1:20 by volume to perform intravenous drip directly.
  • Example 13 paclitaxel intravenous infusion preparation and a kit thereof
  • Afore-obtained paclitaxel solution and medicinal emulsion were respectively loaded in plastic or glass bottles, which were packaged up in a ratio of 1:1 in a same large vessel.
  • the pharmaceutical solution When used, the pharmaceutical solution can be added and evenly dispersed in the emulsion in a ratio of 1:50 by volume to perform intravenous drip directly.
  • Example 14 docetaxel intravenous infusion preparation and kit thereof
  • Afore-obtained docetaxel solution and medicinal emulsion were respectively loaded in plastic or glass bottles, which were packaged up in a ratio of 1:1 in a same large vessel.
  • the pharmaceutical solution When used, the pharmaceutical solution can be added and evenly dispersed in the emulsion in a ratio of 1:75 by volume to perform intravenous drip directly.
  • Example 15 paclitaxel intravenous infusion preparation and a kit thereof
  • Afore-obtained docetaxel solution and medicinal emulsion were respectively loaded in plastic or glass bottles, which were packaged up in a ratio of 1:1 in a same large vessel.
  • the pharmaceutical solution When used, the pharmaceutical solution can be added and evenly dispersed in the emulsion in a ratio of 1:50 by volume to perform intravenous drip directly.
  • Example 16 paclitaxel intravenous infusion preparation
  • the pharmaceutical solution When used, the pharmaceutical solution can be added and evenly dispersed in the commercially available emulsion in a ratio of 1:25 by volume to perform intravenous drip directly.
  • Example 17 paclitaxel intravenous infusion preparation
  • the pharmaceutical solution When used, the pharmaceutical solution can be added and evenly dispersed in the commercially available emulsion in a ratio of 1:40 by volume to perform intravenous drip directly.
  • Example 18 paclitaxel intravenous infusion preparation
  • the pharmaceutical solution When used, the pharmaceutical solution can be added and evenly dispersed in the commercially available emulsion in a ratio of 1:15 by volume to perform intravenous drip directly.
  • Example 19 paclitaxel intravenous infusion preparation
  • Example 20 paclitaxel intravenous infusion preparation
  • the pharmaceutical solution When used, the pharmaceutical solution can be added and evenly dispersed in the commercially available emulsion in a ratio of 1:25 by volume to perform intravenous drip directly.
  • Example 21 paclitaxel intravenous infusion preparation
  • the pharmaceutical solution When used, the pharmaceutical solution can be added and evenly dispersed in the commercially available emulsion in a ratio of 1:25 by volume to perform intravenous drip directly.
  • Example 22 paclitaxel intravenous infusion preparation
  • the pharmaceutical solution When used, the pharmaceutical solution can be added and evenly dispersed in the commercially available emulsion in a ratio of 1:80 by volume to perform intravenous drip directly.
  • the pharmaceutical solution When used, the pharmaceutical solution can be added and evenly dispersed in the commercially available emulsion in a ratio of 1:25 by volume to perform intravenous drip directly.
  • the pharmaceutical solution When used, the pharmaceutical solution can be added and evenly dispersed in the commercially available emulsion in a ratio of 1:25 by volume to perform intravenous drip directly.
  • Example 25 docetaxel intravenous infusion preparation
  • the pharmaceutical solution When used, the pharmaceutical solution can be added and evenly dispersed in the commercially available emulsion in a ratio of 1:25 by volume to perform intravenous drip directly.
  • Example 26 docetaxel intravenous infusion preparation
  • the pharmaceutical solution When used, the pharmaceutical solution can be added and evenly dispersed in the commercially available emulsion in a ratio of 1:25 by volume to perform intravenous drip directly.
  • the pharmaceutical solution When used, the pharmaceutical solution can be added and evenly dispersed in the commercially available emulsion in a ratio of 1:50 by volume to perform intravenous drip directly.
  • Example 28 paclitaxel intravenous infusion preparation
  • the pharmaceutical solution When used, the pharmaceutical solution can be added and evenly dispersed in the commercially available emulsion in a ratio of 1:70 by volume to perform intravenous drip directly.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP10824478.1A 2009-10-23 2010-10-22 Pharmaceutical solution of taxanes comprising ph regulator and preparation method thereof Not-in-force EP2491919B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL10824478T PL2491919T5 (pl) 2009-10-23 2010-10-22 Roztwór farmaceutyczny taksanów zawierający regulator ph i sposób jego wytwarzania

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2009100709318A CN102038635A (zh) 2009-10-23 2009-10-23 一种含有pH值调节剂的紫杉烷类药物溶液及其制备方法
PCT/CN2010/077996 WO2011047637A1 (zh) 2009-10-23 2010-10-22 一种含有pH值调节剂的紫杉烷类药物溶液及其制备方法

Publications (4)

Publication Number Publication Date
EP2491919A1 EP2491919A1 (en) 2012-08-29
EP2491919A4 EP2491919A4 (en) 2013-09-18
EP2491919B1 EP2491919B1 (en) 2016-05-11
EP2491919B2 true EP2491919B2 (en) 2019-06-26

Family

ID=43899845

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10824478.1A Not-in-force EP2491919B2 (en) 2009-10-23 2010-10-22 Pharmaceutical solution of taxanes comprising ph regulator and preparation method thereof

Country Status (11)

Country Link
US (1) US9241922B2 (zh)
EP (1) EP2491919B2 (zh)
JP (1) JP5847722B2 (zh)
KR (1) KR101722398B1 (zh)
CN (2) CN102038635A (zh)
AR (1) AR078736A1 (zh)
AU (1) AU2010310258B2 (zh)
CA (1) CA2765748C (zh)
HK (1) HK1164708A1 (zh)
PL (1) PL2491919T5 (zh)
WO (1) WO2011047637A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009047794A2 (en) * 2007-10-01 2009-04-16 Intas Pharmaceuticals Limited Taxane derivative composition
CN109745287A (zh) 2010-05-03 2019-05-14 帝国制药美国公司 非水性紫杉烷前-乳剂制剂以及制备和使用该制剂的方法
CN101926757B (zh) 2010-09-01 2013-01-02 北京大学 一种难溶性药物的液体组合物及其制备方法
US8842114B1 (en) 2011-04-29 2014-09-23 Nvidia Corporation System, method, and computer program product for adjusting a depth of displayed objects within a region of a display
JP2013194009A (ja) * 2012-03-21 2013-09-30 Nipro Corp ドセタキセル製剤
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
JP6076744B2 (ja) * 2013-01-04 2017-02-08 ナガセ医薬品株式会社 ドセタキセル含有医薬組成物
JP6292267B2 (ja) * 2016-09-13 2018-03-14 ニプロ株式会社 ドセタキセル製剤
JP2018115178A (ja) * 2018-03-15 2018-07-26 ニプロ株式会社 ドセタキセル製剤
CN111153535B (zh) * 2020-01-19 2022-03-25 武汉市新华印刷有限责任公司 一种显影机冲版废水处理系统

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000928A1 (fr) † 1991-07-08 1993-01-21 Rhone-Poulenc Rorer S.A. Nouvelles compositions a base de derives de la classe des taxanes
WO2003053350A2 (en) † 2001-12-20 2003-07-03 Bristol-Myers Squibb Company Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability
WO2004043390A2 (en) † 2002-11-08 2004-05-27 Bristol-Myers Squibb Company Pharmaceutical compositions and methods of using taxane derivatives
US20060067952A1 (en) † 2004-09-28 2006-03-30 Sd Pharmaceuticals, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
WO2007013454A1 (ja) † 2005-07-25 2007-02-01 Usui Kokusai Sangyo Kaisha, Ltd. フューエルデリバリパイプ

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877205A (en) 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
US7030155B2 (en) * 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
CN1535679A (zh) * 2003-04-04 2004-10-13 齐鲁制药厂 含有紫杉醇类物质的药物组合物及其制备方法
US20070202070A1 (en) * 2004-03-31 2007-08-30 Motoaki Kamachi Moisture Retention Polymer Compound
EP1799631B1 (en) * 2004-09-24 2017-01-25 Showa Denko K.K. Hydroxycitric acid derivatives and skin external preparations containing the same
EP1862183B1 (en) * 2005-03-14 2010-11-03 Otsuka Pharmaceutical Factory, Inc. Kit comprising drug and fat emulsion
JP2008543789A (ja) * 2005-06-17 2008-12-04 ホスピラ オーストラリア ピーティーワイ エルティーディー ドセタキセルの液体薬学的処方物
CN101023940A (zh) * 2006-02-20 2007-08-29 郝守祝 一种紫杉烷类化合物的药用组合物、制备方法及用途
US7670997B2 (en) * 2006-06-08 2010-03-02 Bausch & Lomb Incorporated Ophthalmic compositions comprising a branched, glycerol monoalkyl compound and a fatty acid monoester
CN101244053B (zh) * 2007-02-16 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 以多西他赛为主组分的新的分散体系
AU2008269179A1 (en) * 2007-06-22 2008-12-31 Scidose Llc Solubilized formulation of docetaxel without Tween 80
WO2009047794A2 (en) * 2007-10-01 2009-04-16 Intas Pharmaceuticals Limited Taxane derivative composition
CN101288642B (zh) * 2007-11-07 2011-04-27 天津天士力集团有限公司 一种紫杉烷类药物静脉给药制剂及其制备方法
AU2008346121B2 (en) * 2007-12-24 2013-10-10 Sun Pharma Advanced Research Company Limited Nanodispersion

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000928A1 (fr) † 1991-07-08 1993-01-21 Rhone-Poulenc Rorer S.A. Nouvelles compositions a base de derives de la classe des taxanes
WO2003053350A2 (en) † 2001-12-20 2003-07-03 Bristol-Myers Squibb Company Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability
WO2004043390A2 (en) † 2002-11-08 2004-05-27 Bristol-Myers Squibb Company Pharmaceutical compositions and methods of using taxane derivatives
US20060067952A1 (en) † 2004-09-28 2006-03-30 Sd Pharmaceuticals, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
WO2007013454A1 (ja) † 2005-07-25 2007-02-01 Usui Kokusai Sangyo Kaisha, Ltd. フューエルデリバリパイプ

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Appendix VI, pages 50-51", PHARMACOPOEIA OF THE PEOPLE'S REPUBLIC OF CHINA, vol. 2, 2005, pages 923 - 925 †
"Handbook of Pharmaceutical Excipients", 2009, article "Polyethylene Glycol", pages: 517 - 522, 6 ED †
IUPAC COMPENDIUM OF CHEMICAL TERMINOLOGY: "IUPAC. Compendium of Chemical Terminology. The Gold Book, Version 2.3.3", INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY, 24 February 2014 (2014-02-24), pages 1088 - 1090, XP055354099 †
R.G. STRICKLEY: "Solubilizing expients in oral and injectable formulations", PHARM. RES., vol. 21, no. 2, 2004, XP008136709 †

Also Published As

Publication number Publication date
CA2765748C (en) 2016-10-25
AU2010310258B2 (en) 2013-09-19
KR20120087902A (ko) 2012-08-07
PL2491919T3 (pl) 2017-08-31
EP2491919A4 (en) 2013-09-18
KR101722398B1 (ko) 2017-05-17
AR078736A1 (es) 2011-11-30
PL2491919T5 (pl) 2019-12-31
HK1164708A1 (zh) 2012-09-28
CA2765748A1 (en) 2011-04-28
JP5847722B2 (ja) 2016-01-27
JP2013508312A (ja) 2013-03-07
WO2011047637A1 (zh) 2011-04-28
CN102448441A (zh) 2012-05-09
US9241922B2 (en) 2016-01-26
EP2491919B1 (en) 2016-05-11
CN102038635A (zh) 2011-05-04
AU2010310258A1 (en) 2012-01-19
CN102448441B (zh) 2014-09-17
US20120157517A1 (en) 2012-06-21
EP2491919A1 (en) 2012-08-29

Similar Documents

Publication Publication Date Title
EP2491919B2 (en) Pharmaceutical solution of taxanes comprising ph regulator and preparation method thereof
RU2642234C2 (ru) Композиции антагонистов нейрокинина-1 для внутривенного введения
CN101926757B (zh) 一种难溶性药物的液体组合物及其制备方法
AU2018264078A1 (en) Novel analgesic compositions
BR112012027279B1 (pt) composições de emulsão farmacêutica com baixo teor de óleo que compreendem progestogênio
CN109069651A (zh) 稳定的尼莫地平肠胃外制剂
WO2002009667A9 (de) Dispersionen zur formulierung wenig oder schwer löslicher wirkstoffe
JP2015503565A (ja) 安定化させたグルカゴンナノエマルジョン
US20050186230A1 (en) Elemene compositions containing liquid oil
WO2012146057A1 (zh) 一种姜黄素类化合物注射溶液及其静脉注射剂
EP2968575B1 (en) Parenteral diclofenac composition
TW200922552A (en) Novel taxoid-based compositions
CN114344299A (zh) 一种具有长效缓释作用的脂质释药系统及其制备方法
CN102038636B (zh) 一种含有螯合剂的紫杉烷类药物溶液及其制备方法
CN113613632A (zh) 麻醉剂的稳定制剂和相关剂型
TWI511725B (zh) A taxane-containing drug solution containing chelating agent and a preparation method thereof
TWI472340B (zh) Taxanes containing solution and a preparation method of the co-solvent
TWI516282B (zh) A taxane-containing drug solution containing a pH adjusting agent and a preparation method thereof
KR20120000510A (ko) 난용성 트리사이클릭 유도체 화합물의 용해도가 향상된 약학적 조성물
CN102038634B (zh) 一种含有助溶剂的紫杉烷类药物溶液及其制备方法
WO2014033751A2 (en) Pharmaceutical composition of propofol

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20111214

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20130820

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20130813BHEP

Ipc: A61K 31/337 20060101ALI20130813BHEP

Ipc: A61K 9/08 20060101AFI20130813BHEP

Ipc: A61K 47/10 20060101ALI20130813BHEP

Ipc: A61K 47/12 20060101ALI20130813BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: TASLY HOLDING GROUP CO., LTD.

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/08 20060101AFI20150709BHEP

Ipc: A61K 47/10 20060101ALI20150709BHEP

Ipc: A61K 47/12 20060101ALI20150709BHEP

Ipc: A61P 35/00 20060101ALI20150709BHEP

Ipc: A61K 31/337 20060101ALI20150709BHEP

INTG Intention to grant announced

Effective date: 20150728

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20151006

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: JIANGSU TASLY DIYI PHARMACEUTICAL CO., LTD.

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 798066

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160515

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602010033377

Country of ref document: DE

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: PATENTANWAELTE SCHAAD, BALASS, MENZL AND PARTN, CH

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160811

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 798066

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160511

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160912

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160812

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

REG Reference to a national code

Ref country code: DE

Ref legal event code: R026

Ref document number: 602010033377

Country of ref document: DE

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

26 Opposition filed

Opponent name: WITTKOPP, ALEXANDER

Effective date: 20170210

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161022

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161022

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20101022

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161031

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

APBM Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNO

APBP Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2O

APBU Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9O

PUAH Patent maintained in amended form

Free format text: ORIGINAL CODE: 0009272

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT MAINTAINED AS AMENDED

REG Reference to a national code

Ref country code: CH

Ref legal event code: AELC

27A Patent maintained in amended form

Effective date: 20190626

AK Designated contracting states

Kind code of ref document: B2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R102

Ref document number: 602010033377

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: SE

Ref legal event code: RPEO

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20201020

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20201022

Year of fee payment: 11

Ref country code: IT

Payment date: 20201030

Year of fee payment: 11

Ref country code: DE

Payment date: 20201026

Year of fee payment: 11

Ref country code: FR

Payment date: 20201020

Year of fee payment: 11

Ref country code: CH

Payment date: 20201022

Year of fee payment: 11

Ref country code: SE

Payment date: 20201022

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20201021

Year of fee payment: 11

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602010033377

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20211101

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20211022

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211023

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211101

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211022

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220503

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211031

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211022

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211022